Search company, investor...

Founded Year



Series B | Alive

Total Raised


Last Raised

$83M | 6 mos ago

Mosaic Score

+60 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Celsius Therapeutics

Celsius Therapeutics applies a systematic approach to single-cell sequencing, combining massive datasets and complex algorithms in order to discover precision therapies that have an impact on the lives of patients with autoimmune diseases and cancer. By analyzing single cells, Celsius's approach has the potential to understand the causes of disease at an entirely new level of resolution that overcomes limitations of traditional genomic sequencing approaches.

Celsius Therapeutics Headquarters Location

399 Binney Street

Cambridge, Massachusetts, 02139,

United States


ESPs containing Celsius Therapeutics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Life Sciences / Biopharma Tech

These companies provide laboratory equipment and software to sequence, observe, and analyze individual cells. Solutions in this space enable pharma companies to develop therapies based on rare cellular genetics and phenotypes.

Celsius Therapeutics named as Leader among 15 other companies, including Mission Bio, HiFiBiO Therapeutics, and immunai.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Celsius Therapeutics's Products & Differentiation

See Celsius Therapeutics's products and how their products differentiate from alternatives and competitors

  • AI and Single Cell Enabled Novel Therapeutic (ASCENT) platform

    Industrialized single cell genomics methods

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Celsius Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Celsius Therapeutics in 1 CB Insights research brief, most recently on Sep 19, 2022.

Expert Collections containing Celsius Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Celsius Therapeutics is included in 7 Expert Collections, including Digital Health.


Digital Health

21,952 items

Startups recreating how healthcare is delivered


Artificial Intelligence

9,391 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Biopharma Tech

6,079 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Digital Health 150

150 items

The winners of the second annual CB Insights Digital Health 150.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Latest Celsius Therapeutics News

Celsius Therapeutics Names Scientific Advisers

Sep 22, 2022

September 22, 2022 08:30 AM Eastern Daylight Time CAMBRIDGE, Mass.--( BUSINESS WIRE )--Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers. “As Celsius prepares to advance our first programs into the clinic, we are entering a transitional point in our evolution,” said Tariq Kassum, M.D., President and CEO of Celsius. “We are thrilled to welcome this esteemed group of academic leaders – world-renowned experts in inflammatory bowel disease, oncology, immunobiology, single-cell genomics, machine learning and computational biology – to help advance our mission to bring novel precision medicines to patients with cancer and autoimmune disease.” Celsius’ scientific advisers include: Maria T. Abreu, M.D. – Director, Crohn’s and Colitis Center, Professor of Medicine, and Professor of Microbiology and Immunology, University of Miami Miller School of Medicine. Dr. Abreu is an internationally recognized gastroenterologist and physician-scientist specializing in inflammatory bowel disease (IBD) with extensive clinical trial and translational medicine expertise. Richard Flavell, Ph.D., FRS – Sterling Professor of Immunobiology, Yale University School of Medicine; Investigator, Howard Hughes Medical Institute. A molecular biologist and immunobiology expert, Dr. Flavell’s research is fundamental to the understanding of the molecular and cellular basis of innate and adaptive immunity. Peter Kharchenko, Ph.D. – Principal Scientist, Altos Labs San Diego Institute; Gilbert S. Omenn Associate Professor of Biomedical Informatics, Harvard Medical School. One of the world’s leading specialists in transcriptome research and an expert in single-cell genomics, Dr. Kharchenko is focused on statistical and computational methods for analysis of high-throughput assays, with a particular focus on analysis of single-cell datasets. Florian Rieder, M.D. – Vice Chair, Co-director IBD Section; Director, IBD Advanced Fellowship, Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic. A physician scientist with extensive clinical research experience, Dr. Rieder is internationally recognized for his clinical and translational expertise in IBD and has been instrumental in developing clinical guidelines in ulcerative colitis and Crohn’s Disease for the European Crohn’s and Colitis Organization (ECCO). Ton Schumacher, Ph.D. – Senior Member, The Netherlands Cancer Institute; Venture Partner, Third Rock Ventures. A cancer immunology expert, Dr. Schumacher has taken an engineering-based approach to dissect cancer-specific immunity and is internationally recognized for his work to reveal the mechanisms behind T cell recognition of cancer. Nir Yosef, Ph.D. – Associate Professor, Department of Systems Immunology, the Weizmann Institute; Associate Professor, Department of Electrical Engineering and Computer Science, University of California, Berkeley. A computational biologist and expert in single-cell genomics, Dr. Yosef’s research focuses on developing and applying computational tools that leverage single-cell genomics, with the goal of better understanding the factors that contribute to variability between immune cells. About Celsius Therapeutics Celsius Therapeutics is a biotechnology company developing novel precision medicines in autoimmune disease and cancer by harnessing the power of single cell RNA sequencing and human biology at scale. The company’s first therapeutic candidate is an anti-TREM1 antibody for the treatment of inflammatory bowel disease, and the company has multiple ongoing drug discovery programs in oncology. Celsius is based in Cambridge, Mass. For more information, please visit , or follow us on LinkedIn or Twitter . Contacts

Celsius Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Celsius Therapeutics Rank

  • When was Celsius Therapeutics founded?

    Celsius Therapeutics was founded in 2017.

  • Where is Celsius Therapeutics's headquarters?

    Celsius Therapeutics's headquarters is located at 399 Binney Street, Cambridge.

  • What is Celsius Therapeutics's latest funding round?

    Celsius Therapeutics's latest funding round is Series B.

  • How much did Celsius Therapeutics raise?

    Celsius Therapeutics raised a total of $148M.

  • Who are the investors of Celsius Therapeutics?

    Investors of Celsius Therapeutics include Casdin Capital, Alexandria Venture Investments, Heritage Provider Network, Google Ventures, Third Rock Ventures and 8 more.

  • Who are Celsius Therapeutics's competitors?

    Competitors of Celsius Therapeutics include CytoReason and 6 more.

  • What products does Celsius Therapeutics offer?

    Celsius Therapeutics's products include AI and Single Cell Enabled Novel Therapeutic (ASCENT) platform and 2 more.

  • Who are Celsius Therapeutics's customers?

    Customers of Celsius Therapeutics include Servier, University of Oxford, Cleveland Clinic, LMU University Hospital Munich, Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy and the University Health Network and Janssen.

You May Also Like


AliveX generates and combines multi-omics data with systems biology, computational modeling, and AI to advance human health through the decoding of the immune system and identification of novel biomarkers & therapeutic targets. Its integrated multi-omics data generation and computational platforms enable the company and partners to empower discoveries, accelerate clinical trials, and derive actionable insights. AliveX was founded in 2019 and is based in Zurich, Switzerland.

Gero Logo

Gero develops data analysis methods to identify potential targets for therapeutic intervention against age-related diseases and aging. It uses models of statistical physics to analyze gene networks' stability and predict their dynamics over time. The proposed models allow it to link gene network stability with mortality. The company's GeroSense is a mobile app that measures health changes.


BIOS is a neural engineering startup, creating the open standard hardware and software interface between the human nervous system and AI. BIOS is developing the standards, datasets, tools, and algorithms to enable a new generation of neural treatments to improve the quality of life for millions of people affected by chronic disease. Its team combines applied materials, ML, software, neuroscience in conjunction with the experience of surgeons, clinicians and patients to create a seamless and accessible user experience.


BERG is a Boston-based biopharma company focused on taking a bold "back to biology" approach to therapeutic discovery using its unique AI-based Interrogative Biology platform. This platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient's own biology drives the platform's results and guides the company in the discovery and development of drugs, diagnostics and healthcare applications. Its platform utilizes patient population health data to bring actionable Patient Intelligence to precision medicine applications. This means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems.

GNS Healthcare Logo
GNS Healthcare

GNS Healthcare applies artificial intelligence (AI) platform to unravel the complexity of human disease in order to match the right treatment to the right patient at the right time.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine develops a range of generative adversarial networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions that transform the way innovative medicines and treatments are discovered and accelerate research and development. The company was founded in 2014 and is based in Hong Kong.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.